Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00574639 · ClinicalTrials.gov registry record · Early Phase 1
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT00574639 is a Early Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 14 participants.
The verdict
NCT00574639, a Early Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the way by which Alprazolam (Xanax) an anti-anxiety drug affects specialized molecules in your brain called GABA (A) receptors that alter your body's ability to defend itself from low blood sugar (hypoglycemia). We hypothesize that prior activation of GABA (A) receptors may result in blunting of counterregulatory responses during subsequent hypoglycemia and exercise.
Interventions
- DRUG Placebo
- DRUG Alprazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-07 |
| Est. Completion | 2016-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00574639
The ClinicalTrials.gov registry entry for NCT00574639 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00574639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00574639 about?
NCT00574639 is a clinical study titled "Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2". The purpose of this study is to determine the way by which Alprazolam (Xanax) an anti-anxiety drug affects specialized molecules in your brain called GABA (A) receptors that alter your body's ability to defend itself from low blood sugar (hypoglycemia). We hypothesize that prior activation of GABA (...
What is the current status of trial NCT00574639?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2007-07. Estimated completion is 2016-06.
What interventions are being tested in trial NCT00574639?
The interventions under investigation include: Placebo (DRUG), Alprazolam (DRUG).
Who is sponsoring clinical trial NCT00574639?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.